Philippa C. Lavallee

Philippa C. Lavallee

Auto-generated profile, based on publicly available information

Philippa C. Lavallee

APHP, Department of Neurology and Stroke Centre, Bichat Hospital, Université Paris-Cité, Paris, France; INSERM LVTS-U1148, DHU FIRE, Université Paris-Cité, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NPNathan Peiffer-Smadja
Nathan Peiffer-Smadja
ABAntoine Bridier-Nahmias
Antoine Bridier-Nahmias
VFValentine Marie Ferré
Valentine Marie Ferré
CCCharlotte Charpentier
Charlotte Charpentier
MGMathilde Garé
Mathilde Garé
BVBenoit Visseaux
Benoit Visseaux
An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibody monotherapy to prevent severe COVID-19 in high-risk patients. This study aimed to assess the risk of emergence of mutations following treatment with a single monoclonal antibody. Bamlanivimab was administered at a single dose of 700 mg in a one-hour IV injection in a referral center for the management of COVID-19 in France. Patients were closely monitored clinically and virologically with nasopharyngeal RT-PCR and viral whole genome sequencing. Six patients were treated for a nosocomial SARS-CoV-2 infection, all males, with a median age of 65 years and multiple comorbidities. All patients were infected with a B.1.1.7 variant, which was the most frequent variant in France at the time, and no patients had E484 mutations at baseline. Bamlanivimab was infused in the six patients within 4 days of the COVID-19 diagnosis. Four patients had a favorable outcome, one died of complications unrelated to COVID-19 or bamlanivimab, and one kidney transplant patient treated with belatacept died from severe COVID-19 more than 40 days after bamlanivimab administration. Virologically, four patients cleared nasopharyngeal viral shedding within one month after infusion, while two presented prolonged viral excretion for more than 40 days. The emergence of E484K mutants was observed in five out of six patients, and the last patient presented a Q496R mutation potentially associated with resistance. CONCLUSIONS: These results show a high risk of emergence of resistance mutants in COVID-19 patients treated with monoclonal antibody monotherapy.

1 November 2022 in Stroke
Verified
Journal Article
Closed access
PDF file
PAPierre Amarenco
Pierre Amarenco
JKJong S. Kim
Jong S. Kim
JLJulien Labreuche
Julien Labreuche
HCHugo Charles
Hugo Charles
GMGIROUD Maurice
GIROUD Maurice
OIon behalf of the Treat Stroke to Target Investigators
on behalf of the Treat Stroke to Target Investigators
Background: In atherosclerotic stroke, lipid-lowering treatment with a target LDL (low-density lipoprotein) cholesterol of <70 compared with 100±10 mg/dL reduced the risk of subsequent cardiovascular events. This post hoc analysis explored the relative effects of the combination of statin and ezetimibe (dual therapy) and statin monotherapy in achieving the lower LDL cholesterol target and in reducing the risk of major vascular events, as compared with the higher target group. Methods: Patients with ischemic stroke in the previous 3 months or transient ischemic attack within the previous 15 days and evidence of cerebrovascular or coronary artery atherosclerosis were randomly assigned to a target LDL cholesterol of <70 or 100±10 mg/dL, using statin and/or ezetimibe as needed. The primary outcome was the composite of ischemic stroke, myocardial infarction, new symptoms requiring urgent coronary or carotid revascularization, and vascular death. Cox regression model including lipid-lowering therapy as a time varying variable, after adjustment for randomization strategy, age, sex, index event (stroke or transient ischemic attack), and time since the index event. Results: Among 2860 patients enrolled, patients who were on dual therapy during the trial in the lower target group had a higher baseline LDL cholesterol as compared to patients on statin monotherapy (141±38 versus 131±36, respectively, P <0.001). In patients on dual therapy and on statin monotherapy, the achieved LDL cholesterol was 66.2 and 64.1 mg/dL respectively, and the primary outcome was reduced during dual therapy as compared with the higher target group (HR, 0.60 [95% CI, 0.39–0.91]; P =0.016) but not during statin monotherapy (HR, 0.92 [95% CI, 0.70–1.20]; P =0.52), with no significant increase in intracranial bleeding. Conclusions: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu ; Unique identifier: EUDRACT2009-A01280-57.

1 August 2023 in Stroke
Verified
Journal Article
Closed access
PAPierre Amarenco
Pierre Amarenco
PLPhilippa C Lavallée
Philippa C Lavallée
JKJong S Kim
Jong S Kim
JLJulien Labreuche
Julien Labreuche
HCHugo Charles
Hugo Charles
TITreat Stroke to Target Investigators
Treat Stroke to Target Investigators
BACKGROUND: Whether a strategy to target an LDL (low-density lipoprotein) cholesterol 50% from baseline rather than <50% from baseline has not been investigated. METHODS: The Treat Stroke to Target trial was conducted in France and South Korea in 61 sites between March 2010 and December 2018. Patients with ischemic stroke in the previous 3 months or transient ischemic attack within the previous 15 days and evidence of cerebrovascular or coronary artery atherosclerosis were randomly assigned to a target LDL cholesterol of 50% LDL cholesterol reduction from baseline during the trial had a higher baseline LDL cholesterol and a lower LDL cholesterol achieved as compared to patients who had <50% LDL cholesterol reduction (155±32 and 62 mg/dL versus 121±34 and 74 mg/dL, respectively, P <0.001 for both). In the 50% LDL reduction had a significant reduction in the primary outcome as compared to the higher target group (hazard ratio, 0.61 [95% CI, 0.43–0.88]; P =0.007) and patients with <50% LDL reduction from baseline had little reduction (hazard ratio, 0.96 [95% CI, 0.73–1.26]; P =0.75). CONCLUSIONS: In this post hoc analysis of the TST trial, targeting an LDL cholesterol of <70 mg/dL reduced the risk of primary outcome compared with 100±10 mg/dL provided LDL cholesterol reduction from baseline was superior to 50%, thereby suggesting that the magnitude of LDL cholesterol reduction was as important to consider as the target level to achieve. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01252875. URL: https://clinicaltrialsregister.eu ; Unique identifier: EUDRACT2009-A01280-57.

19 August 2021 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
MOMichaël Obadia
Michaël Obadia
CLCedric Lamirel
Cedric Lamirel
EMElena Meseguer
Elena Meseguer
PSPierre Seners
Pierre Seners
KZKevin Zuber
Kevin Zuber
PAPierre Amarenco
Pierre Amarenco

23 February 2022 in JMV-Journal de Médecine Vasculaire
Verified
Journal Article
Closed access
GEGabrielle Assaraf Eshagh
Gabrielle Assaraf Eshagh
MDMathilde Dauguet
Mathilde Dauguet
AGAugustin Gaudemer
Augustin Gaudemer
PLPhilippa Lavallee
Philippa Lavallee

3 July 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
PLPhilippa Lavallee
Philippa Lavallee
HCHugo Charles
Hugo Charles
JLJulien Labreuche
Julien Labreuche
GAGregory W Albers
Gregory W Albers
LCLouis Caplan
Louis Caplan
PAPierre Amarenco
Pierre Amarenco
Objectives The objectives are to assess smoking abstinence and its effects on vascular risk and to report tobacco-cessation counselling and pharmacotherapy use in patients who had a recent minor stroke or transient ischaemic attack (TIA). Design and setting The TIA registry.org project is a prospective, observational registry of patients with TIA and minor stroke that occurred in the previous 7 days with a 5-year follow-up, involving 61 sites with stroke specialists in 21 countries (Europe, Asia, Latin America and Middle East). Of those, 42 sites had 5-year follow-up data on more than 50% of their patients and were included in the present study. Participants From June 2009 through December 2011, 3847 patients were eligible for the study (80% of the initial cohort). Outcomes Tobacco counselling and smoking-cessation pharmacotherapy use in smoking patients were reported at discharge. Association between 3-month smoking status and risk of a major cardiovascular event (MACE) was analysed with multivariable Cox regression model. Results Among 3801 patients included, 835 (22%) were smokers. At discharge, only 35.2% have been advised to quit and 12.5% had smoking-cessation pharmacotherapy prescription. At 3 months, 383/835 (46.9%) baseline smokers were continuers. Living alone and alcohol abuse were associated with persistent smoking; high level of education, aphasia and dyslipidaemia with quitting. The adjusted HRs for MACE at 5 years were 1.13 (95% CI 0.90 to 1.43) in former smokers, 1.31 (95% CI 0.93 to 1.84) in quitters and 1.31 (95% CI 0.94 to 1.83) in continuers. Using time-varying analysis, current smoking at the time of MACE non-significantly increased the risk of MACE (HR 1.31 (95% CI 0.97 to 1.78); p=0.080). Conclusion In the TIAregistry.org, smoking-cessation intervention was used in a minority of patients. Surprisingly, in this population in which, at 5 years, other vascular risk factors were well controlled and antithrombotic treatment maintained, smoking cessation non-significantly decreased the risk of MACE.